Dermata Therapeutics, Inc. DRMA
1.14
(0.03)
(2.56%)
as of 25 Sep
- Market cap
- $4.7M
- P/E
- 0.0×
Follow DRMA
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 1.20 | 0.16 | 7.66 | 7.53 | 4.91 | 1.79 | 4.79 |
Net Debt/EBITDA |
— | 0.16 | (0.98) | 1.38 | 0.65 | 0.92 | 0.25 | 0.97 |
Debt/Assets |
0.00% | 62.14% | 585.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (6.11) | (1.12) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.83 | 1.24 | 0.54 | 0.92 | 0.82 | 0.91 | 1.03 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | — | — | — | — |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 19.58% | 13.42% | 134.00% | (119.18%) | (125.96%) | (310.44%) | (194.20%) | |
| — | (457.10%) | (242.32%) | (171.14%) | (103.52%) | (104.46%) | (213.46%) | (132.63%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (1,376.50%) | 101.84% | (103.54%) | (159.60%) | (122.65%) | (787.11%) | (121.45%) |
Average Days of Receivables |
— | — | — | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (4,902.87) | (5,035.62) | (3,163.00) | (1,920.48) | (328.66) | (72.96) | (8.38) |
Cash per Share |
— | 2,489.75 | 663.00 | 5,999.33 | 1,356.80 | 381.44 | 20.66 | 8.12 |
Shareholders Equity per Share |
— | (262.75) | (3,972.37) | 5,615.06 | 1,309.11 | 325.90 | 10.20 | 6.72 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (262.75) | (3,972.37) | 5,615.06 | 1,309.11 | 325.90 | 10.20 | 6.72 |
Free Cash Flow |
— | (3.92) | (4.03) | (5.69) | (8.83) | (6.41) | (11.16) | (7.76) |
Working Capital |
— | 0.34 | (3.18) | 10.11 | 6.02 | 6.36 | 1.56 | 6.22 |
Net Current Asset Value |
— | (0.21) | (3.18) | 10.11 | 6.02 | 6.36 | 1.56 | 6.22 |
| Other line items | ||||||||
Quick Ratio |
— | 1.16 | 0.14 | 7.12 | 6.76 | 4.58 | 1.60 | 4.59 |
Depreciation/Fixed assets |
— | 477.00 | 0.00 | 0.00 | — | — | — | — |
Cash ROIC |
— | (127.97%) | (448.56%) | (27.23%) | (72.04%) | (46.46%) | (236.37%) | (56.44%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | — | — | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (4,902.87) | (5,035.62) | (3,163.00) | (1,920.48) | (328.66) | (72.96) | (8.38) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 0.22 | 0.22 | 0.31 | 0.51 | 0.68 | 0.84 | 0.63 |
Average Assets |
— | 1.03 | 1.34 | 6.11 | 9.28 | 7.46 | 5.76 | 5.70 |
Average Common Equity |
— | (24.11) | (24.11) | (7.81) | 8.06 | 6.19 | 3.96 | 3.89 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates